Investigating how Cannabinoid Receptor 2 protects blood vessels after brain injuries.
The role of Cannabinoid Receptor 2 in cerebrovascular protection following traumatic brain injury
This study is looking at how a specific receptor in the brain, called CB2, might help protect blood vessels after a traumatic brain injury, with the hope of finding new ways to reduce inflammation and improve recovery for people who have experienced such injuries.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10829804 on NIH RePORTER |
What this research studies
This research explores the role of Cannabinoid Receptor 2 (CB2) in protecting the brain's blood vessels following traumatic brain injury (TBI). TBI can cause significant damage to the brain, leading to both immediate and delayed effects, including inflammation and vascular disruption. By targeting the CB2 receptor, the research aims to develop new treatments that could mitigate the harmful inflammatory response and improve recovery outcomes for patients. The study will involve laboratory experiments to understand how activating CB2 can help restore normal function to the blood-brain barrier and reduce secondary injury effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a traumatic brain injury, particularly those showing signs of inflammation or vascular issues.
Not a fit: Patients with non-traumatic brain injuries or those who do not exhibit significant inflammatory responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery and quality of life for patients with traumatic brain injuries.
How similar studies have performed: Previous research has shown promising results in targeting the endocannabinoid system for neuroprotection, suggesting that this approach may be effective in treating TBI.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Bullock, Trent a — Temple Univ of the Commonwealth
- Study coordinator: Bullock, Trent a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.